A massive raft of fire ants found on Lake Travis
When their underground nests flood, fire ants link their legs and jaws together to create buoyant, self-assembled mounds. These floating colonies can contain thousands of ants — and they can still bite or sting if disturbed.
These fire ant colonies can contain thousands of worker ants, and can still bite or sting those who interfere with the floating colony.
Fire ants are widespread in Texas, and researchers at Texas A&M University are studying how they respond to flooding. The insects bite one another and interlock their limbs, forming tightly packed rafts that don't sink. Their waxy skin helps repel water and keep the group afloat.
'It's called a self-organizing or self-assembling process. And it's something only social insects do,' LeBrun said. A research scientist at the University of Texas' Brackenridge Field Lab in central Austin, LeBrun has researched ants for three decades.
'There are a lot of other structures that ants make in a similar way. For example, army ants will make bridges across rivers,' LeBrun said, but still, this raft is rare. Fire ants he believes are the only ants that do this.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 minutes ago
- USA Today
Could this California company challenge SpaceX's Falcon 9? What to know about Rocket Lab
Rocket Lab has increasingly been in the news over mounting anticipation for the first launch of its upcoming Neutron rocket. Rocket Lab, a spaceflight company based in California, has spent years building up a reputation as a reliable launch service provider for small satellites. Now, though, the venture has its sights set on bigger targets: Procuring some of those lucrative government and commercial contracts that have long been the domain of Elon Musk's Texas-based SpaceX. Maybe you've heard about Rocket Lab's diminutive Electron launch vehicle, which the company bills as the second-most active rocket in the U.S. Or maybe you've heard about its next-generation Neutron spacecraft, which could soon be making its inaugural flight from Virginia. Whichever may be the case, here's everything to know for those interested in Rocket Lab and its future plans for spaceflight. What is Rocket Lab? Rocket Lab is a launch service provider and spaceflight company founded in 2006 and based in Long Beach, California. The company operates out of three launch pads at two launch sites, including one in New Zealand and two in Virginia at the Mid-Atlantic Regional Spaceport within NASA's Wallops Flight Facility. Rocket Lab Neutron launch date Rocket Lab has increasingly been in the news over mounting anticipation for the first launch of its upcoming Neutron rocket. The satellite launch vehicle is central to Rocket Lab's plans to shift from small satellite deployments to missions with heavier payloads. But when exactly the Neutron rocket could make its orbital debut has yet to be determined. Rocket Lab continues to work through a checklist of requirements before Neutron can get off the ground for its maiden flight. That includes integrating – or stacking – the rocket stages and getting its commercial launch license from the Federal Aviation Administration, according to the company's first-quarter earnings presentation provided to the USA TODAY Network. The good news? Construction on infrastructure at the launch pad is on schedule, according to the report. Earlier in July, Rocket Lab also announced that the company had awarded a contract to shipbuilder Bollinger Shipyards to support the build of a 400-foot ocean landing platform named "Return On Investment." But the challenge for Rocket Lab will be in transporting the components of the Neutron to the facility, according to the website TechCrunch. The vehicle must be shipped in segments to Rocket Lab's Launch Complex 3 in Virginia, where it will be fully mated as a rocket. Could Neutron challenge SpaceX, Falcon 9? Many space industry analysts have said that Neutron could emerge as a credible challenger to SpaceX's Falcon 9 in the medium-lift launch market. Rocket Lab is developing the Neutron rocket – which already has contracts with the Department of Defense – for commercial, civil and military space operations. That includes satellite constellation deployments, cargo resupply missions to the International Space Station and interplanetary missions. The arena is one that SpaceX, founded by billionaire Elon Musk in 2002, has dominated for years with its Falcon 9 rocket – one of the most active rockets in the world. The Falcon 9 is routinely the rocket of choice to launch NASA astronaut missions to the International Space Station and is the exclusive launch provider for Musk's Starlink satellite deliveries. At 141-feet-tall, Neutron is smaller in stature than SpaceX's two-stage, 230-foot Falcon 9. But like the Falcon 9, Neutron is designed to be reusable so that it can launch more frequently. Its design features an integrated system that brings Neutron's first stage and payload fairings back to Earth as a single stage. Capable of delivering about a 14-ton (more than 28,600 pounds) payload to low-Earth before landing, Neutron is powered by Rocket Lab's newly developed Archimedes engine. Rocket Lab's emergence also comes at a time of mounting public discord between Musk and President Donald Trump. What is Rocket Lab's Electron rocket? Rocket Lab has already spent years reliably launching its smaller Electron rocket to deliver small satellites and other payloads to orbit for civil and commercial contractors. At 59 feet tall, Electron is capable of carrying just 661 pounds of cargo to space, according to Rocket Lab. A version of the rocket is also tailored for Rocket Lab's hypersonic HASTE launches. One of the two launch complexes where Electron can launch is right next door to the Neutron's new launch complex. Since its first orbital launch in January 2018, the Electron has delivered more than 200 satellites to orbit and become one of the most frequently launched U.S. rockets, second only to the Falcon 9, according to Rocket Lab. In June alone, the Electron launched four times on both government and commercial missions, according to Rocket Lab. The most recent mission came June 28 when the Electron launched a single satellite to space for "a confidential commercial customer," Rocket Lab announced in a press release. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the company. Is Rocket Lab a good stock to buy? Whether to invest Unlike SpaceX, Rocket Lab is publicly traded. While Rocket Lab's stock is up 800% over the past year, according to Forbes, the company is not yet profitable. "A lot hinges on Rocket Lab's ability to evolve its revenue model and reach sustained profitability," Sasirekha Subramanian, an equity research content expert, wrote for Forbes. Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@
Yahoo
5 hours ago
- Yahoo
This 1 Habit Will Transform the Quality of Your Sleep, Says New Study
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new study suggests that consistent workout routines raises the likelihood of sleeping well. The more times people did at least 10 minutes of moderate-to-vigorous physical activity during a five-day period, the better, deeper sleep they had. Here's why doctors and experts say the secret to better sleep lies in your sweat seshes. If your bedtime routine features an intensive, multi-step process with an arsenal of tools, you might find yourself wondering if there's an easier way to conk out at night. While sleep masks, sound machines, and sleepy girl mocktails can help (sorta), your solution for better sleep may be as easy as just getting regular exercise. That's the big takeaway from new research published in the Journal of Physical Activity & Health. The researchers discovered that having a consistent workout routine raises the odds of logging the deep, restorative sleep of your dreams. Given that regular exercise is good for your health in plenty of other ways, this seems like a health hack worth trying. Here's why doctors are all about it. Meet the experts: Chris Corral, co-lead study author and an exercise scientist at The University of Texas at Austin; Bert Mandelbaum, MD, sports medicine specialist and co-director of the Regenerative Orthobiologic Center at Cedars-Sinai Orthopaedics in Los Angeles; W. Christopher Winter, MD, a neurologist and sleep medicine physician with Charlottesville Neurology and Sleep Medicine and host of the Sleep Unplugged podcast. What did the study find? For the study, researchers had 69 adults wear a Fitbit to track their physical activity and sleep over eight months. The participants also took surveys three times a week that asked them to rank their levels of energy, stress, contentment, and sleep quality in the morning. The researchers found that people who had more days with at least 10 minutes of moderate-to-vigorous physical activity within a five-day period had better, deeper sleep than those who got less exercise. People who exercised also said that they felt like they had more energy and less stress the next morning compared to participants who had less activity in their lives. Why is good sleep connected to exercise? For starters, exercise increases the supply of neurotransmitters that lead to better sleep, says W. Christopher Winter, MD, a neurologist and sleep medicine physician with Charlottesville Neurology and Sleep Medicine and host of the Sleep Unplugged podcast. Specifically, an increase in the neurotransmitter adenosine is likely the biggest reason exercise helps us sleep, although changes in the feel-good hormones dopamine and serotonin are important, too, Dr. Winter points out. Secondly, regular exercise routines tap into your circadian rhythm. 'Exercise, particularly if it happens around the same time every day, provides a circadian cue that allows the brain to know where it is in its 24-hour day,' Dr. Winter says. 'We call this a zeitgeber. Regular exercise is an important one.' Exercise can also boost your mood, and that can positively impact both how you sleep and feel about sleep, Dr. Winter says. How much exercise do I need to get to reap the sleep benefits? According to the findings in this study, not a lot. Even light movement, like taking regular walks or standing breaks, was linked with better sleep and a boosted mood the next day. Still, 'more is likely better,' says Chris Corral, co-lead study author and an exercise scientist at The University of Texas at Austin. Spreading your exercise out throughout the week also seems to be more helpful for sleep than being a weekend warrior, he says. Bert Mandelbaum, MD, sports medicine specialist and co-director of the Regenerative Orthobiologic Center at Cedars-Sinai Orthopaedics in Los Angeles, agrees. 'You should have daily exercise for better sleep—and health,' he says. What kinds of workouts are the best to promote sleep? Any exercise that gets your heart rate up can be helpful, Corral says. 'There are benefits to both light intensity and moderate-to-vigorous intensity for sleep, although moderate-to-vigorous provides more health benefits beyond sleep, offering a higher return on investment,' he says. Corral also lists weight training, Pilates, and bodyweight exercise, as being helpful, along with yoga and stretching for relaxing. Move more, get better sleep. It's a win-win for your health. Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
a day ago
- Yahoo
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas, July 24, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules." Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic "self/non‑self" checks largely unaddressed. LENSai's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome "humanness" scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Study Highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity "self" scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Read the full case study: [link] About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," "potential," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@
